Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TTRX
Strong SellHot AirTurn Therapeutics Inc. · Healthcare · United States · $299M · Avg Vol: $989K/d
13
StockRankGet insider-trade alerts
Q
14
V
20
M
57
P/E (TTM)
—
ROE
-686.3%
D/E
8.9x
Dividend %
—
COMPANY DESCRIPTION
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — | 0.5M | 5.0M | — |
| EPS | -0.08 | -0.06 | -0.12 | — | -0.28 | -0.40 | -0.39 | — |
| Shares | 29.4M | 29.4M | 29.4M | 0.0% | 30.4M | — | — | — |
| Debt | 25.2K | 0.1M | 80.4K | 78.7% | — | — | — | — |
| Equity | 85.8K | -0.2M | 4.7M | 639.2% | — | — | — | — |
| Op CF | -1.4M | -1.4M | -2.6M | — | -4.3M | — | — | — |
| Inv CF | -44.3K | -99.5K | -0.2M | — | — | — | — | — |
| Fin CF | 0.5M | 1.2M | 6.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+62.2%
SMA 50SMA 200
Close
$13.38
RSI (14)
78.2
52W High
$26.50
From 52W High
0.5%
SCORE BREAKDOWN
Quality
14
ROIC
-95.1%6.9
ROE
-686.3%1.3
GP/Assets
-13.3%6.0
Op. Margin
0.0%38.1
FCF/Assets
n/mN/A
Piotroski
438.9
Int. Cover
—N/A
D/E Ratio
8.91x1.1
Current Ratio
1.19x16.3
Value
20
P/E (TTM)
—N/A
EV/EBITDA
-33.8x25.0
P/FCF
n/mN/A
P/B
426.1x0.1
P/S
—N/A
Div Yield
—N/A
Momentum
57
52W High %
50%24.3
RS 6M
261%99.8
SMA 50/200
1.75x99.8
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
+46%52.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$299M
P/E (Forward)
-65.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TTRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TTRX | Turn Therapeutics Inc.(you) | $299M | 13 | Strong Sell |
| IVVD | Invivyd, Inc. | $284M | 12 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 12 | Strong Sell |
| PYXS | Pyxis Oncology, Inc. | $269M | 15 | Strong Sell |
| SION | Sionna Therapeutics, Inc. | $265M | 14 | Strong Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 17 | Strong Sell |
| ELDN | Eledon Pharmaceuticals, Inc. | $260M | 15 | Strong Sell |
| DMAC | DiaMedica Therapeutics Inc. | $345M | 16 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%